Indian Journal of Pharmacology Home 

DRUG WATCH
[View FULLTEXT] [Download PDF]
Year : 2014  |  Volume : 46  |  Issue : 1  |  Page : 125--126

Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma

Mehmet A. N. Sendur1, Sercan Aksoy2, Nuriye Yildirim Özdemir1, Nurullah Zengin1 
1 Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey
2 Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

Correspondence Address:
Mehmet A. N. Sendur
Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara
Turkey

Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.


How to cite this article:
Sendur MA, Aksoy S, Özdemir NY, Zengin N. Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma.Indian J Pharmacol 2014;46:125-126


How to cite this URL:
Sendur MA, Aksoy S, Özdemir NY, Zengin N. Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma. Indian J Pharmacol [serial online] 2014 [cited 2020 Sep 29 ];46:125-126
Available from: http://www.ijp-online.com/article.asp?issn=0253-7613;year=2014;volume=46;issue=1;spage=125;epage=126;aulast=Sendur;type=0